PMID- 31024302
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Hydroxysafflor Yellow A Alleviates Ovalbumin-Induced Asthma in a Guinea Pig Model 
      by Attenuateing the Expression of Inflammatory Cytokines and Signal Transduction.
PG  - 328
LID - 10.3389/fphar.2019.00328 [doi]
LID - 328
AB  - Hydroxysafflor yellow A (HSYA) is an effective ingredient of the Chinese herb 
      Carthamus tinctorius L. In this study, we aimed to evaluate the effects of HSYA 
      on ovalbumin (OVA)-induced asthma in guinea pigs, and to elucidate the underlying 
      mechanisms. We established a guinea pig asthma model by intraperitoneal injection 
      and atomized administration OVA. Guinea pigs were injected intraperitoneally with 
      HSYA (50, 75, 112.5 mg/kg) once daily from days 2 to 22 before OVA 
      administration. We examined biomarkers including lung function, pulmonary 
      histopathology, immunoglobulin E (IgE), Th1/Th2 relative inflammatory mediators, 
      and related pathways. Pathological changes in lung tissues were detected by 
      hematoxylin and eosin and periodic acid-Schiff staining. Phosphorylation levels 
      of JNK mitogen-activated protein kinase (MAPK), p38 MAPK, ERK MAPK, and inhibitor 
      of nuclear factor kappaBalpha (IkappaBalpha) were detected by western blot. plasma levels of 
      total IgE, platelet-activating factor (PAF), and interleukin (IL)-3 were detected 
      by enzyme-linked immunosorbent assay (ELISA). Expression levels of tumor necrosis 
      factor (TNF)-alpha, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-13, and interferon (IFN)-gamma were 
      detected by ELISA and real-time quantitative polymerase chain reaction. HSYA 
      significantly reduced airway resistance, improved dynamic lung compliance, and 
      attenuated the pathologic changes. HSYA also inhibited the phosphorylation of JNK 
      MAPK, p38 MAPK, ERK MAPK, and IkappaBalpha, and inhibited the OVA-induced elevations of 
      IgE, PAF, IL-1beta, IL-6, IL-4, IL-5, and IL-13 and the decreases in TNF-alpha, IFN-gamma, 
      IL-2, and IL-3. These findings suggest that HSYA has a protective effect on 
      OVA-induced asthma through inhibiting the Th1/Th2 cell imbalance and inhibiting 
      activation of the MAPK signaling pathway.
FAU - Zheng, Meng
AU  - Zheng M
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
FAU - Guo, Xinjing
AU  - Guo X
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
FAU - Pan, Ruiyan
AU  - Pan R
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
FAU - Gao, Jianwei
AU  - Gao J
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
FAU - Zang, Baoxia
AU  - Zang B
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
FAU - Jin, Ming
AU  - Jin M
AD  - Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20190405
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6459898
OTO - NOTNLM
OT  - Hydroxysafflor yellow A
OT  - MAPK pathway
OT  - Th1
OT  - Th2
OT  - asthma
OT  - inflammation
EDAT- 2019/04/27 06:00
MHDA- 2019/04/27 06:01
PMCR- 2019/04/05
CRDT- 2019/04/27 06:00
PHST- 2018/04/26 00:00 [received]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/04/27 06:00 [entrez]
PHST- 2019/04/27 06:00 [pubmed]
PHST- 2019/04/27 06:01 [medline]
PHST- 2019/04/05 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00328 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Apr 5;10:328. doi: 10.3389/fphar.2019.00328. eCollection 
      2019.